‘OK,’ I said. ‘Let’s go for it.’ I was in. The CBF would make the starting materials for the vaccine – about 100 ml of ‘seed stock’ from which all batches of clinical-grade vaccine would be made. Sarah would approach a selection of manufacturers we had worked with before to try to secure manufacturing slots to make the clinical-grade vaccine later in the year, and also, as a backup, feel out the funders of our next clinical-grade manufacturing project, due to start later that year, about the possibility of delaying if necessary.
